drugset / Trial / NCT07363460
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
RandomizedParallel-groupDouble-blindTreatment
Summary
A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis
Timeline
- Start
- 2025-11-18
- Primary completion
- 2027-11-05
- Completion
- 2028-07-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | HSK39297 | Unknown | 200 mg | Oral |
| Comparator | HSK39297 | Unknown | 300 mg | Oral |